HALO Halozyme Therapeutics Inc

$66.97

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 10/6/2025

About Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company is headquartered in San Diego, California.

Website: https://halozyme.com

Sector
LIFE SCIENCES
Industry
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1159036
Address
11388 SORRENTO VALLEY ROAD, SAN DIEGO, CA, US
Valuation
Market Cap
$7.26B
P/E Ratio
17.14
PEG Ratio
-2.50
Price to Book
19.96
Performance
EPS
$3.43
Dividend Yield
—
Profit Margin
43.70%
ROE
198.40%
Technicals
50D MA
$60.34
200D MA
$55.83
52W High
$66.00
52W Low
$37.97
Fundamentals
Shares Outstanding
124M
Target Price
$68.12
Beta
1.32

HALO EPS Estimates vs Actual

● Estimated
● Actual

HALO News & Sentiment

Oct 06, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Are Medical Stocks Lagging Armata Pharmaceuticals ( ARMP ) This Year?
Here is how Armata Pharmaceuticals, Inc. (ARMP) and Halozyme Therapeutics (HALO) have performed compared to their sector so far this year.
Oct 02, 2025 • Zacks Commentary BULLISH
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Sep 29, 2025 • Zacks Commentary NEUTRAL
AbbVie Seeks FDA Nod for Tavapadon to Treat Parkinson's Disease
ABBV files for FDA approval of tavapadon, a once-daily oral Parkinson's drug backed by late-stage TEMPO studies.
Sep 29, 2025 • Zacks Commentary BULLISH
Is Janus Henderson Small/Mid Cap Growth Alpha ETF ( JSMD ) a Strong ETF Right Now?
Smart Beta ETF report for ...
Sep 26, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Encompass Health Opens First Connecticut Rehab Hospital in Danbury
EHC opens its first Connecticut rehab hospital in Danbury, boosting its nationwide expansion and meeting rising demand for specialized care.
Sep 25, 2025 • Zacks Commentary NEUTRAL
HRMY Stock Down as Fragile X Syndrome Study Fails to Meet Goal
Harmony Biosciences' shares plunge after ZYN002 failed in Fragile X, but Wakix sales and new epilepsy assets keep its pipeline moving forward.
Sentiment Snapshot

Average Sentiment Score:

0.300
50 articles with scored sentiment

Overall Sentiment:

Bullish

HALO Reported Earnings

May 05, 2025
Mar 31, 2025 (Pre market)
0.0 Surprise
  • Reported EPS: $0.00
  • Estimate: $0.97
  • Whisper: —
  • Surprise %: 0.0%
Feb 18, 2025
Dec 31, 2024 (Pre market)
0.1 Surprise
  • Reported EPS: $1.26
  • Estimate: $1.16
  • Whisper: —
  • Surprise %: 8.7%
Oct 31, 2024
Sep 30, 2024 (Post market)
0.29 Surprise
  • Reported EPS: $1.27
  • Estimate: $0.98
  • Whisper: —
  • Surprise %: 29.6%
Aug 06, 2024
Jun 30, 2024 (Post market)
0.15 Surprise
  • Reported EPS: $0.91
  • Estimate: $0.76
  • Whisper: —
  • Surprise %: 19.7%
May 07, 2024
Mar 31, 2024 (Post market)
0.09 Surprise
  • Reported EPS: $0.79
  • Estimate: $0.70
  • Whisper: —
  • Surprise %: 12.9%
Feb 20, 2024
Dec 31, 2023 (Post market)
-0.01 Surprise
  • Reported EPS: $0.82
  • Estimate: $0.83
  • Whisper: —
  • Surprise %: -1.2%
Nov 06, 2023
Sep 30, 2023 (Post market)
0.04 Surprise
  • Reported EPS: $0.75
  • Estimate: $0.71
  • Whisper: —
  • Surprise %: 5.6%
Aug 08, 2023
Jun 30, 2023 (Post market)
0.11 Surprise
  • Reported EPS: $0.74
  • Estimate: $0.63
  • Whisper: —
  • Surprise %: 17.5%
May 09, 2023
Mar 31, 2023 (Post market)
-0.01 Surprise
  • Reported EPS: $0.47
  • Estimate: $0.48
  • Whisper: —
  • Surprise %: -2.1%

Financials